Roche provides update on phase III Ocrevus (ocrelizumab) high dose study in people with relapsing multiple sclerosis
Roche announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in… read more.
